AXSM vs NMRA
AXSM: A fully integrated biopharmaceutical company developing innovative CNS treatments, with three FDA-approved commercial products and a deep pipeline of novel candidates. NMRA: Neumora Therapeutics is a clinical-stage biotechnology company developing precision medicine therapies for psychiatric and neurodegenerative brain disorders.
Side-by-side fundamentals
| Metric | AXSM | NMRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $239.62 | $1.54 | |
| Market cap as of 2026-07-23 | $12.3B | $298M | |
| PEG as of 2026-07-23 | 2.51 | n/a | |
| Net margin as of 2026-07-23 | -26.6% | n/a | |
| Gross margin as of 2026-07-23 | +92.6% | n/a | |
| Operating margin as of 2026-07-23 | -25.9% | n/a | |
| ROE as of 2026-07-23 | -260.0% | -181.7% | NMRA higher |
| ROA as of 2026-07-23 | -27.8% | -119.2% | AXSM higher |
| Debt / equity as of 2026-07-23 | 3.61 | 0.75 | NMRA lower |
| Revenue growth (YoY) as of 2026-07-23 | +63.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +133.7% | n/a | |
| Beta as of 2026-07-23 | 0.73 | 2.85 | |
| 1-year return as of 2026-07-22 close | +116.0% | -17.6% | AXSM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.